Is Catalyst Pharmaceutical Partners, Inc. (CPRX) a "Buy" after Its Promising Results In Proof-Of-Concept Trial Of Vigabatrin
Earlier today Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) has announced promising top-line results in proof-of-concept trial of its CPP-109 (Vigabatrin).
